Oncotarget

Research Papers:

Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance

Min Young Lee, Austin Yeon, Muhammad Shahid, Eunho Cho, Vikram Sairam, Robert Figlin, Khae-Hwan Kim and Jayoung Kim _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:13231-13243. https://doi.org/10.18632/oncotarget.24229

Metrics: PDF 640 views  |   HTML 1069 views  |   ?  


Abstract

Min Young Lee1, Austin Yeon2, Muhammad Shahid2, Eunho Cho3, Vikram Sairam3, Robert Figlin4, Khae-Hwan Kim5 and Jayoung Kim2,3,4,5

1Institute for Systems Biology, Seattle, WA, USA

2Department of Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA

3University of California Los Angeles, Los Angeles, CA, USA

4Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

5Department of Urology, Ga Cheon University College of Medicine, Incheon, South Korea

Correspondence to:

Jayoung Kim, email: Jayoung.Kim@cshs.org

Khae-Hwan Kim, email: kimcho99@gilhospital.com

Keywords: lipidomics; cisplatin resistance; bladder cancer

Received: October 06, 2017     Accepted: January 06, 2018     Published: January 13, 2018

ABSTRACT

Due to its tendency to recur and acquire chemoresistance quickly, bladder cancer (BC) remains to be an elusive and difficult disease. Patients with recurrent and chemoresistant BC have an extremely poor prognosis. One possible approach that may provide insightful and valuable information regarding resistance mechanisms is looking into the lipid metabolism of BC cells. Metabolism of lipids is essential for cancer cells and is associated with the regulation of a variety of key cellular processes and functions. This study conducted a comparative lipidomic profiling of two isogenic human T24 bladder cancer cell lines, one of which is clinically characterized as cisplatin-sensitive (T24S) and the other as cisplatin-resistant (T24R). Immunohistochemistry analysis revealed that expression of cytosolic acetyl-CoA synthetase 2 (ACSS2) is positively correlated with aggressive BC. Ultra performance liquid chromatography-mass spectrometry (UPLC-MS) analysis profiled a total of 1,864 lipids and levels of differentially expressed lipids suspected of being associated with cisplatin resistance were determined. In addition, we found that ACSS2 inhibition greatly perturbed levels of metabolites, including CE(18:1), CE(22:6), TG(49:1), and TG(53:2). This study broadens our current knowledge on the links between cisplatin resistance and lipid metabolism in aggressive BC and suggests potential biomarkers for identifying higher-risk patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24229